Abstract
The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development.
| Original language | English |
|---|---|
| Pages (from-to) | 28-31 |
| Journal | European journal of oncology pharmacy |
| Volume | 5 |
| Issue number | 1 |
| Publication status | Published - 2011 |
| Externally published | Yes |